PA(16:0/18:2(9Z,12Z)) (BioCAD00000021731)
Metabolite Card
Formula: C37H69O8P (672.473)
SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@]([H])(COP(O)(=O)O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC
Synonyms [en]
PA(16:0/18:2(9Z,12Z)); PA(34:2); 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate; 1-Palmitoyl-2-linoleoyl-sn-glycero-3-phosphate; PA(16:0/18:2); Phosphatidic acid(34:2)
Last reviewed on 2024-06-28.
Cite this Page
PA(16:0/18:2(9Z,12Z)). 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000021731). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
PA(16:0/18:2(9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/18:2(9Z,12Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the linoleic acid moiety is derived from seed oils. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).
DBLinks
- CAS Registry Number:
- PubChem CID: 9547167
- ChEBI: 73259
- HMDB: HMDB0007860
- LipidMaps: LMGP10010023
- KEGG: C00416
- BioCyc: CPD-8265
- NCBI MeSH:
- Wikipedia:
Other DBLinks
- PubChem: 9547167
- ChEBI: ChEBI:73259
- HMDB: HMDB0007860
- LipidMaps: LMGP10010023
- KEGG: C00416
- BioCyc: CPD-8265
- RefMet: RM0133480
- Metlin: METLIN_40921
Class / Ontology
- WishartLab ClassyFire: [Glycerophosphates] Glycerophosphates
- RefMet: [PA] PA
- LipidMaps: [Diacylglycerophosphates [GP1001]] Diacylglycerophosphates [GP1001]
- ChEBI: [CHEBI:73259] 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| PathBank:SMP0027263 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0027267 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/16:1(9Z)/16:1(9Z)) |
| PathBank:SMP0027271 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:0/18:2(9Z,12Z)) |
| PathBank:SMP0027275 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:1(11Z)/18:2(9Z,12Z)) |
| PathBank:SMP0027279 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:1(9Z)/18:2(9Z,12Z)) |
| PathBank:SMP0027283 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z)) |
| PathBank:SMP0027287 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0027291 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)) |
| PathBank:SMP0027295 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0027299 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0027303 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0032746 | De Novo Triacylglycerol Biosynthesis TG(16:0/18:2(9Z,12Z)/20:3(8Z,11Z,14Z)) |
| PathBank:SMP0068404 | De Novo Triacylglycerol Biosynthesis TG(16:0/18:2(9Z,12Z)/20:4(5Z,8Z,11Z,14Z)) |
| PathBank:SMP0068712 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/16:0/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0068716 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/16:1(9Z)/16:1(9Z)) |
| PathBank:SMP0068720 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:0/18:2(9Z,12Z)) |
| PathBank:SMP0068724 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:1(11Z)/18:2(9Z,12Z)) |
| PathBank:SMP0068728 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:1(9Z)/18:2(9Z,12Z)) |
| PathBank:SMP0068732 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z)) |
| PathBank:SMP0068736 | Cardiolipin Biosynthesis CL(16:0/18:2(9Z,12Z)/18:2(9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |